SCHEMBL4559413

SCHEMBL4559413

CCC(CO)Nc1nc(Nc2cccc([N+](=O)[O-])c2)c2ncn(C(C)C)c2n1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 18/20 0.74
CDK5R1 Q15078 15/20 0.74
KDM4E B2RXH2 2/20 0.74
MAPT P10636 2/20 0.74
NPC1 O15118 1/20 0.74
POLB P06746 1/20 0.74
CDK2 P24941 16/20 0.68
CCNA2 P20248 14/20 0.68
CDK1 P06493 5/20 0.68
CDK7 P50613 3/20 0.68
CDK9 P50750 3/20 0.68
CSNK1A1 P48729 2/20 0.68
CCNB1 P14635 2/20 0.68
CCNE1 P24864 2/20 0.68
CCNT1 O60563 1/20 0.68
CCNH P51946 1/20 0.68
MNAT1 P51948 1/20 0.68
GSK3B P49841 1/20 0.68
DYRK1A Q13627 14/20 0.67
CCNA1 P78396 13/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4559411 1.00 CDK5 (0.74) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL4490485 0.89 CDK5 (0.73) CDK5CDK5R1KDM4EMAPTCDK2
SCHEMBL4490493 0.89 CDK5 (0.73) CDK5CDK5R1KDM4EMAPTCDK2
SCHEMBL28453366 0.85 CDK5 (0.80) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL28453367 0.85 CDK5 (0.80) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL22651813 0.85 CDK5 (0.83) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL13638194 0.84 CDK5 (0.76) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL20792022 0.81 CDK5 (1.00) CDK5CDK5R1KDM4EMAPTNPC1
SCHEMBL29435003 0.81 CDK5 (1.00) CDK5CDK5R1KDM4EMAPTNPC1
Hydrochloric Acid SCHEMBL29562722 0.80 CDK5 (0.98) CDK5CDK5R1KDM4EMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612079-B2 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-11-03 US disclosed
EP-1399446-B1 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LTD (GB) 2005-08-03 EP disclosed
US-20050009846-A1 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009846-A1 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders TYMP, PNP, IMPDH1 CDK5 83/4885CDK5R1 107/4885KDM4E 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.